PR

Precipio, Inc.

PRPOHealthcareNASDAQ

Diagnostics & Research · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$24.0M
+29.8% YoY
Net Income
-$363,000
+91.5% YoY
EBITDA
$1.5M
+154.1% YoY
Free Cash Flow
$642,750

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 14 Below MA2000.3% below MA200
Jul 13 Below MA2001.0% below MA200
About Precipio, Inc.

Headquartered within the healthcare sector, Precipio, Inc. focuses on Diagnostics & Research services and products. Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. With a market capitalization of $42.4M, it sits in micro-cap territory. It provides diagnostic blood cancer testing services.

Where PRPO stands vs its 150-day and 200-day moving averages

As of the July 14, 2026 close, PRPO finished 4.76% below its 150-day moving average ($25.20) and 0.25% below its 200-day moving average ($24.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PRPO overbought or oversold?

At the July 14, 2026 close, PRPO's RSI(14) was 54.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$42.4M
Fwd P/E60.77
EPS$-0.45
Beta1.28
52W Change+71.7%
ROE-7.1%
Analysis

The company holds $2.6M in cash, though total debt stands at $3.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $643K supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -7.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $9.4M (2022) to $24.0M (2025), reflecting a 156% increase over the period.

Investors considering Precipio, Inc. should weigh the typical risks associated with PRPO's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRPO.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
PRPO: Precipio, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance